Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diabetes.

Guardado en:

Detalles Bibliográficos
Autores principales:	Li-Ming Gan, Maria Lagerström-Fermér, Leif G. Carlsson, Cecilia Arfvidsson, Ann-Charlotte Egnell, Anna Rudvik, Magnus Kjaer, Anna Collén, James D. Thompson, John Joyal, Ligia Chialda, Thomas Koernicke, Rainard Fuhr, Kenneth R. Chien, Regina Fritsche-Danielson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/4edc38b69f3e4b73a58e9dddd556b69b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4edc38b69f3e4b73a58e9dddd556b69b
record_format	dspace
spelling	oai:doaj.org-article:4edc38b69f3e4b73a58e9dddd556b69b2021-12-02T14:38:44ZIntradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes10.1038/s41467-019-08852-42041-1723https://doaj.org/article/4edc38b69f3e4b73a58e9dddd556b69b2019-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-08852-4https://doaj.org/toc/2041-1723Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diabetes.Li-Ming GanMaria Lagerström-FermérLeif G. CarlssonCecilia ArfvidssonAnn-Charlotte EgnellAnna RudvikMagnus KjaerAnna CollénJames D. ThompsonJohn JoyalLigia ChialdaThomas KoernickeRainard FuhrKenneth R. ChienRegina Fritsche-DanielsonNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Li-Ming Gan Maria Lagerström-Fermér Leif G. Carlsson Cecilia Arfvidsson Ann-Charlotte Egnell Anna Rudvik Magnus Kjaer Anna Collén James D. Thompson John Joyal Ligia Chialda Thomas Koernicke Rainard Fuhr Kenneth R. Chien Regina Fritsche-Danielson Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
description	Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diabetes.
format	article
author	Li-Ming Gan Maria Lagerström-Fermér Leif G. Carlsson Cecilia Arfvidsson Ann-Charlotte Egnell Anna Rudvik Magnus Kjaer Anna Collén James D. Thompson John Joyal Ligia Chialda Thomas Koernicke Rainard Fuhr Kenneth R. Chien Regina Fritsche-Danielson
author_facet	Li-Ming Gan Maria Lagerström-Fermér Leif G. Carlsson Cecilia Arfvidsson Ann-Charlotte Egnell Anna Rudvik Magnus Kjaer Anna Collén James D. Thompson John Joyal Ligia Chialda Thomas Koernicke Rainard Fuhr Kenneth R. Chien Regina Fritsche-Danielson
author_sort	Li-Ming Gan
title	Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
title_short	Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
title_full	Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
title_fullStr	Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
title_full_unstemmed	Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
title_sort	intradermal delivery of modified mrna encoding vegf-a in patients with type 2 diabetes
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/4edc38b69f3e4b73a58e9dddd556b69b
work_keys_str_mv	AT liminggan intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT marialagerstromfermer intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT leifgcarlsson intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT ceciliaarfvidsson intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT anncharlotteegnell intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT annarudvik intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT magnuskjaer intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT annacollen intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT jamesdthompson intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT johnjoyal intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT ligiachialda intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT thomaskoernicke intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT rainardfuhr intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT kennethrchien intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes AT reginafritschedanielson intradermaldeliveryofmodifiedmrnaencodingvegfainpatientswithtype2diabetes
_version_	1718390892767739904

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Ejemplares similares